PENTASA
PENTASA

Code :

Price: Contact

Manufacturer                          
  •       LABORATOIRES GALDERMA
Present/Packing          Pentasa PR tab 500 mg x 100's
                                      Pentasa supp 1 g x 28's
Price                    

Features    
     

Delivery




Share this product to others


All 0 rating

Shopping
guide
Add to cart

PENTASA

Manufacturer:

          Ferring

Contents:

          Mesalazine.

Indications:

          Tab: Ulcerative colitis & Crohn's disease. Supp: Ulcerative proctitis.

Contraindications:

          Hypersensitivity to salicylates. Severe hepatic or renal impairment.

Special Precautions:

          Renal & hepatic impairment. Monitor renal function during initial phase of treatment. Pregnancy & lactation. Infant & childn <2 yr. Tab: Hypersensitivity to sulphasalazine. Discontinue use if mesalazine-induced cardiac hypersensitivity reactions & serious blood dyscrasias occur. Supp: Discontinue if haematological effects, inflammation of cardiac muscle, bleeding, sore throat or bruises occur.

Dosage:

          Tab Individualised dosage. Ulcerative colitis Adult Active: Up to 4 g daily in divided doses. Maintenance: 2 g daily in divided doses. Childn 20-30 mg/kg body wt daily in divided doses. Crohn's disease Adult Up to 4 g daily in divided doses. Childn 20-30 mg/kg body wt daily in divided doses. Supp Ulcerative proctitis Adult 1 supp once-bd.

Class:

          GIT Regulators, Antiflatulents & Anti-Inflammatories

Presentation/Packing:

          Pentasa PR tab 500 mg x 100's
          Pentasa supp 1 g x 28's

Details:

          MyPhuocPharmacy – (08) 62581003

Mesalazine.

Tab Individualised dosage. Ulcerative colitis Adult Active: Up to 4 g daily in divided doses. Maintenance: 2 g daily in divided doses. Childn 20-30 mg/kg body wt daily in divided doses. Crohn's disease Adult Up to 4 g daily in divided doses. Childn 20-30 mg/kg body wt daily in divided doses. Supp Ulcerative proctitis Adult 1 supp once-bd.

Updating

Renal & hepatic impairment. Monitor renal function during initial phase of treatment. Pregnancy & lactation. Infant & childn <2 yr. Tab: Hypersensitivity to sulphasalazine. Discontinue use if mesalazine-induced cardiac hypersensitivity reactions & serious blood dyscrasias occur. Supp: Discontinue if haematological effects, inflammation of cardiac muscle, bleeding, sore throat or bruises occur.